What happened with ENTA today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Enanta Pharmaceuticals licenses hepatitis C drug compounds to AbbVie, which pays for their development, manufacturing and commercialization. Its compound glecaprevir is part of AbbVie’s combination treatment sold as MAVYRET in the United States and MAVIRET elsewhere. Nearly all Enanta’s revenue comes from royalties on this treatment, calculated on the share of sales attributed to glecaprevir rather than the entire combination.
This income depends on AbbVie’s sales, pricing and ability to reach patients; AbbVie alone controls commercialization. Enanta sold a majority share of its future MAVYRET/MAVIRET royalty payments to an OMERS affiliate for upfront cash. That arrangement runs for a limited term, subject to a payment cap, so Enanta retains only part of the cash royalties it earns.
Enanta also develops its own small-molecule drugs for viral diseases and immune-related conditions, but none of its wholly owned candidates has regulatory approval. It retains their commercial rights and is evaluating partnerships rather than having a fixed plan to build its own sales operation. Its AbbVie agreement also restricts Enanta from conducting or licensing other protease-inhibitor activity while a candidate under that agreement is being developed or commercialized.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Beyond AbbVie’s hepatitis C sales, Enanta’s prospects hinge on clinical success in RSV and immunology, with Shionogi and Ark Biosciences developing rival RSV antivirals.
Enanta depends on AbbVie, which licenses its hepatitis C drug ingredients and pays royalties from sales of MAVYRET/MAVIRET; those payments account for substantially all of Enanta’s revenue. Watch sales of this regimen, its pricing and the number of patients treated—not AbbVie’s overall growth.
Gilead Sciences competes for the hepatitis C patients whose treatment with AbbVie’s MAVYRET/MAVIRET generates Enanta’s royalties. Watch competition from its Epclusa, Vosevi and Harvoni, including authorized generic versions of Epclusa and Harvoni, for pressure on AbbVie’s market share and pricing.
Atea Pharmaceuticals is developing oral hepatitis C antiviral combinations that could compete with AbbVie’s regimen, putting the sales that fund Enanta’s royalties at risk.
Evommune is developing oral drugs targeting MRGPRX2 for the chronic spontaneous urticaria and atopic dermatitis patients Enanta also seeks to treat. Watch EVO756’s Phase 2b results in patients whose urticaria persists despite antihistamines, a concrete test of this competing treatment.
Celldex Therapeutics’ barzolvolimab, an antibody targeting KIT in Phase 3 trials for chronic spontaneous urticaria, competes with the treatments Enanta is developing for those patients. Its Phase 3 progress is the development to watch for Enanta’s urticaria ambitions.
Pfizer’s PAXLOVID sales and development of ibuzatrelvir compete with Enanta’s work on COVID-19 antivirals. Watch ibuzatrelvir’s Phase 3 progress: Enanta identifies it as the most advanced oral direct-acting antiviral candidate, alongside an existing U.S. treatment market for high-risk patients who are not hospitalized.
Kymera Therapeutics’ oral STAT6 program competes for the atopic dermatitis patients Enanta’s immunology programs seek to treat. Watch its Phase 1 clinical progress as a competing oral approach in a market Enanta describes as dominated by biologic medicines.
Sanofi challenges Enanta on two fronts: its oral drugs in development compete for chronic spontaneous urticaria patients, while its RSV prevention product BEYFORTUS can reduce demand for Enanta’s prospective RSV treatments. Watch its early Phase 1 oral KIT programs and its Phase 3 RSV vaccine work in infants and toddlers.
Gilead Sciences Inc earningsGILD
Gilead Sciences’ report will show how its hepatitis C treatments compete with AbbVie’s MAVYRET/MAVIRET for patients and sales, which generate royalties for Enanta.
Watch sales of Gilead’s hepatitis C treatments and compare their direction with sales and pricing for AbbVie’s MAVYRET/MAVIRET. Strong Gilead performance alongside pressure on AbbVie would point to competition that could erode Enanta’s royalty base; weaker Gilead sales with steady AbbVie sales would suggest less pressure from this rival.
ABBVIE INC. earningsABBV
AbbVie’s report will show how sales and pricing of MAVYRET/MAVIRET are changing; royalties from this hepatitis C regimen account for substantially all of Enanta’s revenue.
Focus on MAVYRET/MAVIRET sales and pricing, not AbbVie’s overall growth. Steady sales and prices would support Enanta’s royalty stream; falling sales or prices would put pressure on the revenue base that funds its operations and research.
Kymera Therapeutics, Inc. earningsKYMR
Kymera Therapeutics’ report will show whether its oral STAT6 program is advancing for atopic dermatitis, a condition Enanta also seeks to treat.
Look for clinical progress in the STAT6 program and evidence that it may work. Clear progress would mean Enanta faces another oral drug candidate in atopic dermatitis; limited progress would leave this competitive threat at an early stage.
Pfizer Inc. earningsPFE
Pfizer’s report will show how its oral COVID-19 antiviral ibuzatrelvir is progressing in Phase 3, in a treatment market Enanta is also pursuing.
Watch ibuzatrelvir’s Phase 3 progress and evidence. Smooth progress would bring a competing candidate closer to the market for high-risk patients who are not hospitalized, making Enanta’s path more competitive; delays or insufficient evidence would make that pressure less immediate.
Enanta Pharmaceuticals, Inc earningsThis company
Enanta’s report will show whether royalties from AbbVie’s hepatitis C drugs continue to provide meaningful support for its research and development spending.
Read hepatitis C royalties alongside research and development spending and operating cash use. Steady royalties with controlled spending would show the AbbVie collaboration is still helping fund the pipeline; falling royalties or rising spending would mean Enanta must rely more on cash reserves and future financing to keep development moving.
